Cardiometabolic Risk Summit

Day 2 Sessions

On Saturday, October 21 at the Cardiometabolic Risk Summit (CRS), join us for a day focused on the treatment and management of CVD and Lipids with ten sessions that will include Q&A with the expert faculty panel.

Day 2 of the agenda includes Advancing Hyperlipidemia Treatment: Integrating PCSK9 Inhibitors into Optimal Treatment Plans co-presented by CRS Steering Committee Member Michael J. Bloch, MD, FACP, FASH, FSVM, FNLA and CRS co-chair Margo B. Minissian, PhD, ACNP, CLS, AACC, FAHA. This session will include a review of the use of PCSK9 inhibitors as an alternative to statin therapy and the latest clinical trial data, and guidelines to facilitate the incorporation of PCSK9s into treatment plans.

This is just one of the CVD and Lipids sessions presented by expert faculty throughout the program. Other sessions include:

	Applying CVD/Lipids Guidelines in Your Practice
	Update on Statin Therapy
	The Role of HDL-C in Cardiovascular Disease
	Specialized Approaches to Managing Hypercholesterolemia in Patients with Prediabetes and T2DM
	Clinical Trial Update: What’s on the Horizon in CVD/Lipids?
	Managing Triglycerides to Reduce Cardiovascular Risk

Earn up to 21 CME/CNE/CPE credits at the year’s most important meeting devoted to the diagnosis, management, and prevention of cardiometabolic disease, including hypertension, diabetes, dyslipidemia, obesity, and more.

See the full agenda and register online or call 800-208-8075 to reserve your spot at Early Bird Rates that are less than $15 per credit!